List of prodrugs - PsychonautWiki

List of prodrugs

A prodrug is a chemical compound that, after administration, is metabolized (i.e. converted within the body) into a pharmacologically active substance.[1] Inactive prodrugs are pharmacologically inactive compounds that are metabolized into an active form within the body. Instead of administering a drug directly, a corresponding prodrug might be used instead to improve how a medicine is absorbed, distributed, metabolized, and excreted (ADME).

Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract. A prodrug may be used to improve how selectively the drug interacts with cells or processes that are not its intended target. This reduces adverse or unintended effects of a drug.

Prodrugs may be subject to a rate-limiting step in the conversion from inactive to active substance: in which case, only the duration, and not the intensity of the effect increases. Additionally, they may display other differences relating to pharmacokinetic factors (i.e. how a substance is absorbed, distributed, metabolized and excreted) compared its nonprodrug form.[citation needed]

Examples of recreational psychoactive substances that act as prodrugs include GBL (prodrug for GHB), psilocybin (prodrug for psilocin), ALD-52 (prodrug for LSD).











See also

External links


  1. C. G. Wermuth, C. R. Ganellin, P. Lindberg, L. A. Mitscher; Ganellin; Lindberg; Mitscher (1998). "Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)". Pure and Applied Chemistry. 70 (5): 1129.
  2. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. ( / NCBI) |
  3. The advantages of benzonal as an inducer of the liver mono-oxygenase enzyme system compared to phenobarbital. ( / NCBI) |
  4. Benzonal metabolism in guinea pigs. ( / NCBI) |
  5. Deposition of diazepam and its metabolites in hair following a single dose of diazepam. ( / NCBI) |
  6. Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ( / NCBI) |
  8. Sawynok J (January 1986). "The therapeutic use of heroin: a review of the pharmacological literature". Can. J. Physiol. Pharmacol. 64 (1): 1–6. doi:10.1139/y86-001. PMID 2420426. 
  9. Morphine: pharmacokinetics and clinical practice. ( / NCBI) |
  10. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ( / NCBI) |
  11. The excretion of pethidine and its derivatives ( / NCBI) |
  12. <
  13. <
  14. Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. ( / NCBI) |
  15. Recent Advances in Anaesthesia and Intensive Care |
  16. 16.0 16.1 16.2 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. ( / NCBI) |
  18. Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats ( / NCBI) |
  19. Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity. ( / NCBI) |
  20. Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ( / NCBI) |
  21. Determination of aminorex in human urine samples by GC-MS after use of levamisole. ( / NCBI) |
  22. (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. ( / NCBI) |
  23. 23.0 23.1 Active drug metabolites. An overview of their relevance in clinical pharmacokinetics. ( / NCBI) |
  24. Metabolites of naloxone in human urine. ( / NCBI) |
  25. Atypical Psychotropic Agents |
  26. Comparative Pharmacology of Risperidone and Paliperidone. ( / NCBI) |
  27. Engberg, G. O. R. A. N., Elebring, T. H. O. M. A. S., & Nissbrandt, H. (1991). Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Journal of Pharmacology and Experimental Therapeutics, 259(2), 841-847.